Is Alkem Laboratories (ALKEM) overvalued or fairly valued?

MarketChacha shows Alkem Laboratories's valuation in context — a forward P/E of about 23.2, a price-to-book of about 4.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Alkem Laboratories's revenue?

Alkem Laboratories reported revenue of ₹9,664 Cr for FY2026, with net profit of ₹2,282 Cr, per official filings.

What is the share price of Alkem Laboratories (ALKEM)?

Alkem Laboratories last traded at ₹5,190.00 (-0.4% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Alkem Laboratories

ALKEM · NSE · Pharma · India

Snapshot

TickerALKEM

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees19,346

HeadquartersMumbai, India

Websitewww.alkemlabs.com

Filings tracked11

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.

Who owns it

Promoters62.4%
Institutions27.6%
Public & other10.0%

165 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend8.5% → 15.6%

Margin has expanded by about 7.2 points — the business is getting more profitable.

Growth qualityrev 6% · PAT 24%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,118 Cr · EPS 54.60

Est. earnings growth -4.0%

Next fiscal year

Rev ₹18,572 Cr · EPS 223.31

Est. earnings growth +17.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹14,712 Cr

Net margin

15.6%

Revenue CAGR (3y)

+8.2%

Profit CAGR (3y)

+32.7%

Net profit (FY2026)

₹2,302 Cr

Ask MarketChacha about ALKEM

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹14,712 Cr	₹2,302 Cr	15.6%
FY2025	₹12,965 Cr	₹2,165 Cr	16.7%
FY2024	₹12,668 Cr	₹1,796 Cr	14.2%
FY2023	₹11,599 Cr	₹984 Cr	8.5%

Quarterly

Period	Revenue	Net profit	Net margin
Q4 FY26	₹3,603 Cr	₹236 Cr	6.6%
Q3 FY26	₹3,737 Cr	₹636 Cr	17.0%
Q2 FY26	₹4,001 Cr	₹765 Cr	19.1%
Q1 FY26	₹3,371 Cr	₹664 Cr	19.7%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find attached herewith Scrutinizer Report for 52nd Annual General Meeting of the Company.
BSE8/27/2026material
Earnings Call Transcript
Please find attached herewith Q1 FY27- Earnings Call Transcript.
BSE8/20/2026
Earnings Call Transcript
Please find attached herewith Q1 FY27- Earnings Call Transcript.
BSE8/20/2026
Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting
Please find attached herewith Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer''s Report on e-voting.
BSE8/17/2026
Update On US FDA Inspection At Company'S Manufacturing Facility Located At Amaliya, Daman
Please find attached herewith intimation about update on US FDA inspection at Company''s Manufacturing Facility Located at Amaliya, Daman.
BSE8/6/2026
Change in Management
Please find attached herewith regarding Appointment of Senior Management Personnel.
BSE8/3/2026
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached herewith Disclosure under Regulation 30 of the SEBI (LODR) Regulation 2015.
BSE7/30/2026
Notice Of 52Nd Annual General Meeting And Annual Report For FY 2025-26.
Please find attached herewith the Notice of AGM alongwith the Annual Report for the FY 2025-2026.
BSE7/29/2026material
Business Responsibility and Sustainability Reporting (BRSR)
Please find attached herewith the Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026.
BSE7/29/2026
Reg. 34 (1) Annual Report.
Please find enclosed herewith the Notice of the 52nd Annual General Meeting of the Company scheduled to be held on Thursday, 27th August, 2026 at 11.00 a.m. through Video Conferencing (VC)/ ....
BSE7/29/2026
Change in Management
Please find attached herewith Intimation regarding Resignation of Senior Management Personnel.
BSE7/23/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.